Basel
Switzerland
20
2025-08-21
The entities that hold a legal rights for patent applications filed by inventor Luangsay Souphalone:
Souphalone Luangsay from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:
PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV
#2 | 2024-12-26PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV
#3 | 2024-12-12COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1
#4 | 2024-06-06ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSION
#5 | 2024-05-23METHOD FOR THE DETECTION OF ORGAN DERIVED EXTRACELLULAR VESICLES
#6 | 2024-05-09USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#7 | 2023-10-19OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
#8 | 2023-08-17USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#9 | 2023-06-22USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#10 | 2023-06-15USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#11 | 2023-04-20USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#12 | 2023-04-20USE OF SARAF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#13 | 2023-04-20USE OF SCAMP3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#14 | 2022-08-11Enhanced oligonucleotides for inhibiting RTEL1 expression
#15 | 2022-02-03ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSION
#16 | 2021-05-20Oligonucleotides for reduction of PD-L1 expression
#17 | 2021-01-28Use of FUBP1 inhibitors for treating hepatitis B virus infection
#18 | 2020-08-06Oligonucleotides for reduction of PD-L1 expression
#19 | 2020-02-13Oligonucleotides for reduction of PD-L1 expression
#20 | 2017-10-05OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
2001177 ⎘